动物造模,巨细胞病毒疫苗,埃博拉病毒 z-bio 2021-12-16 424

　　In addition to demonstrating the anti-Ebola virus effect of the cytomegalovirus vaccine, the researchers also studied its protective mechanism. The herpes virus vaccine can theoretically produce target proteins (such as Ebola virus glycoprotein) at different times after vaccination.

　　At present, the cytomegalovirus vaccine will produce Ebola virus glycoprotein in the later stage of vaccination. This result of producing a large number of Ebola virus antibodies without detecting Ebola-specific T cells is surprising. The immune conversion of this antibody has never been seen before in primate sporangia virus vaccines. Sporangia virus vaccines usually react with a large number of T cells, with little or no reaction with antibodies. "This is a completely unexpected discovery." said Dr. Michael Jarvis, who is in charge of the project at the University of Plymouth.

　　"Although we need to further explore the study, the results of the study indicate that we may be biased against the immune function of antibodies or T cells based on the target antigen. This is an exciting thing, not because of the Ebola virus, but It is the treatment of other infectious and non-communicable diseases by vaccines." The devastating effect of the Ebola virus on the number of wild great apes in Africa is largely an unexplainable story.

　　Although the current study uses direct vaccination, cytomegalovirus vaccine can be passed from animal to animal, which may be a way to protect this inaccessible animal population. The current research is an improvement. It is not only the application of the traditional Ebola virus vaccine in humans, but also the "self-transmitting vaccine" before it is applied to humans, against the apes Ebola virus and other wild animals. Progress in the treatment of infectious diseases.